Core Viewpoint - Globus Medical, Inc. will announce its financial results for Q4 and the full year ended December 31, 2025, on February 24, 2026, after market close [1] Group 1: Financial Results Announcement - The financial results will be available on the Globus Medical website [1] - A teleconference will be held to discuss the performance with the investment community at 4:30 p.m. Eastern Time on the same day [2] - Participants can access the conference call live via webcast on the Investors page of the Globus Medical website [2] Group 2: Participation Details - Telephone participants must register in advance to receive a confirmation email with details on how to join the call, including a dial-in number and unique passcode [3] - An audio archive of the call will be available on the Investors page after the event [3] Group 3: Company Overview - Globus Medical, Inc. is a leading global musculoskeletal company focused on addressing unmet clinical needs and improving lives [4] - The company emphasizes innovation, education, clinical support, and advancements in various medical fields including spine, orthopedic trauma, and joint reconstruction [4]

Core Viewpoint - The AI sector remains promising, with significant growth potential and opportunities for investment despite recent volatility in stock prices [7][40][67]. Market Overview - The AI stocks experienced a sell-off similar to previous market declines, with the S&P 500 dropping approximately 15% during a recent period [8]. - The current market is characterized by confusion, with geopolitical events influencing investor behavior and leading to volatility in both tech and safe haven sectors [17][22]. AI Sector Insights - The global AI market is projected to grow from $539 billion in 2026 to over $3 trillion by 2033, driven by investments from major tech companies and increasing demand for data centers [40][42]. - Adoption of AI technologies is expanding across various sectors, including healthcare and manufacturing, indicating a long-term trend rather than a temporary phase [15][20]. Stock Recommendations - The top 10 AI stocks recommended show an average revenue growth rate of 38% and an EPS growth rate of 99%, significantly outperforming the S&P 500 and the Magnificent Seven stocks [66][67]. - Specific stocks highlighted include: - **Lumentum Holdings (LITE)**: Up 402% in the last year, with a long-term growth rate of 61% [70]. - **Micron Technology (MU)**: Up 387% in the last year, with a long-term growth rate of 51% [72]. - **Ciena (CIEN)**: Up 215% in the last year, with a long-term EPS growth CAGR of 44% [74]. - **General Motors (GM)**: Up 76% in the last year, utilizing AI for enhanced vehicle connectivity [79]. - **Taiwan Semiconductor Manufacturing (TSM)**: Up 71% in the last year, with strong growth metrics [80]. - **Credo Technology (CRDO)**: Despite recent declines, it has strong growth potential with a forward EPS growth rate of 248% [97]. - **AppLovin (APP)**: Up almost 1000% within Alpha Picks, with a long-term growth rate of 48% [98]. - **Globus Medical (GMED)**: In the healthcare sector, showing strong growth metrics [100]. Investment Strategy - The strategy emphasizes buying on dips, particularly for stocks with strong fundamentals that have recently experienced price declines [35][106]. - The quant model used for stock selection focuses on multiple factors, including growth, value, and profitability, ensuring a diversified approach to investment [51][60].

Core Viewpoint - Globus Medical, Inc. is a prominent player in the medical device industry, focusing on musculoskeletal disorders and competing with major companies like Medtronic and Stryker [1] Stock Performance - Over the past month, GMED's stock price has increased by approximately 4.44%, indicating strong investor confidence and positive market sentiment [2] - In the last 10 days, the stock experienced a slight decline of about 0.70%, which may present a buying opportunity for investors [2] Growth Potential - GMED's stock has a growth potential of 9.14%, appealing to growth-oriented investors [3] - The company's financial health is highlighted by a Piotroski Score of 8, indicating solid fundamentals in profitability, liquidity, and operational efficiency [3] Analyst Insights - Analysts have set a target price of $100.20 for GMED, suggesting potential for higher valuations [4] - The stock recently touched a local minimum, which may signal a potential rebound, encouraging investors to consider entering a position [4]

Core Insights - The U.S. equity markets in Q4 2025 were influenced by optimism regarding potential monetary easing and caution related to economic growth and valuations [1] - The Meridian Growth Fund reported a quarterly return of -0.39%, underperforming the Russell 2500 Growth Index which returned 0.33% [1] - The Fund's focus remains on high-quality businesses with strong competitive advantages and sustainable earnings growth as it approaches 2026 [1] Company Highlights - Globus Medical, Inc. (NYSE:GMED) was highlighted as a leading contributor to the Meridian Growth Fund, focusing on healthcare solutions for musculoskeletal disorders [2] - The stock of Globus Medical, Inc. had a one-month return of 5.77% and a 52-week gain of 0.04%, closing at $92.98 per share with a market capitalization of $12.558 billion on January 26, 2026 [2] - The company reported a re-acceleration in its core spine business to double-digit growth, with evidence of renewed market share gains and improved operating leverage expected in 2026 [3]

Core Insights - Globus Medical, Inc. (NYSE:GMED) is a leading medical device company focused on healthcare solutions in the musculoskeletal sector, known for its innovative products and strong emphasis on research and development [1] Performance Summary - Over the past month, GMED has gained approximately 4.71%, indicating strong upward momentum in a volatile healthcare sector [2] - Despite a slight dip of 0.36% in the last 10 days, this presents a potential buying opportunity as the stock approaches a local minimum, suggesting a possible rebound [2] Growth Potential - GMED has an estimated upside of 5.16%, indicating significant growth potential and making it an attractive option for investors seeking growth opportunities in the healthcare sector [3] Financial Health - The company boasts a robust Piotroski Score of 8, reflecting a strong financial position and the ability to generate profits and manage financial resources effectively [4] - Analysts have set a target price of $97.75 for GMED, which aligns with its growth potential and reflects confidence in the stock's ability to reach this level [5][6]

Core Insights - Globus Medical, Inc. (GMED) is increasing its market share in the musculoskeletal solutions sector, driven by strong performance in implantable devices, biologics, accessories, and surgical instruments across various procedures [2] - The company has shown consistent innovation through a rapid introduction of new products, contributing to its solid financial health [2] - Despite these strengths, macroeconomic challenges and competitive disadvantages pose risks to GMED's operations [2] Financial Performance - Over the past year, GMED's stock has risen by 1.2%, contrasting with a 3.5% decline in the industry and a 17.3% increase in the S&P 500 [3] - The company has a market capitalization of $12.51 billion and an earnings yield of 4.2%, significantly higher than the industry's 0.6% [3] - GMED has exceeded earnings estimates in three of the last four quarters, with an average surprise of 16.2% [3] Growth Drivers - The U.S. Spine business is experiencing ongoing momentum, with notable gains in expandables, minimally invasive screws, and other platforms [5] - The core trauma product portfolio has seen a revenue increase of 17.2% year-over-year in the third quarter [6] - GMED plans to expand its international presence and has recently acquired Nevro, unlocking a $2.5 billion market opportunity [7] Product Development - The company maintains a steady pace of product development, with a focus on active surgeon input and team-oriented approaches [8] - Recent product launches include the ANTHEM Elbow Fracture System and DuraPro with Navigation, among others [11] - The Advanced Materials Science (AMS) implant portfolio has been expanded with new products, indicating a rich R&D pipeline [12] Financial Stability - As of the end of the third quarter, GMED had cash and cash equivalents of $371.8 million and no short-term or long-term debt, indicating strong financial stability [13] - The company has sufficient liquidity to fund growth and acquisitions without financial strain [13] Challenges - GMED faces macroeconomic pressures, including interest rate fluctuations and inflation, which could negatively impact its financial performance [14] - There is a persistent challenge of lower demand for healthcare products, which may affect pricing and sales cycles [16] - Industry consolidation could lead to price concessions and exclusion from certain markets, posing additional risks [17] Earnings Estimates - The Zacks Consensus Estimate for GMED's 2025 earnings per share has increased by 3.5% to $3.80, with revenues expected to rise by 14.5% to $2.88 billion [18]

Group 1 - Bank stocks are facing complex challenges and benefits heading into 2026 after an unusually strong year, raising questions about the sustainability of the rally [5] - Globus Medical (GMED) is experiencing accelerating growth in Q3, with robust earnings and sales outlooks, indicating potential for further gains as it breaks out of a base [5] - The medical sector, led by Globus Medical, is highlighted as one of the top-performing sectors in the Investor's Business Daily database [5] Group 2 - Growth stocks have outperformed for two consecutive days, contributing to the S&P 500 reaching a record high [6] - The stock market is seeing a rally in health care names, with Medtronic and Globus Medical being notable mentions [10] - AI stocks, including Google, are trading near buy points, with one being named a 'Top Stock' for 2026 [8]

Core Viewpoint - The article aims to provide informational content regarding investment opportunities and risks, emphasizing the importance of independent research and verification by readers [2][3]. Group 1: Company Analysis - The article does not provide specific details about any particular company or its financial performance, focusing instead on general investment advice [2][3]. Group 2: Industry Insights - There are no specific insights or analyses related to any industry mentioned in the article, as it primarily serves as a general informational piece [2][3].

Group 1: Biotechnology and Healthcare Companies Performance - Several biotechnology and healthcare companies experienced notable gains in after-hours trading due to clinical updates, financial results, and upcoming industry presentations [1] Group 2: ALX Oncology Holdings Inc. - ALX Oncology Holdings Inc. (ALXO) surged 10.17% to $1.30 after announcing positive data from a Phase 2 trial of its lead candidate, evorpacept, in combination with rituximab and lenalidomide for patients with indolent B-cell non-Hodgkin lymphoma [2] - The findings are scheduled to be presented on December 7, 2025, at the American Society of Hematology (ASH) Annual Meeting in Orlando, Florida [2] Group 3: Globus Medical, Inc. - Globus Medical, Inc. (GMED) climbed 9.34% to $99.00 following preliminary unaudited sales results, reporting fourth-quarter 2025 sales of approximately $823.2 million, a 25.2% increase year-over-year [3] - Full-year 2025 sales are expected to reach $2.936 billion, representing a 16.5% increase from the prior year [3] - The company set its 2026 revenue guidance between $3.18 billion and $3.22 billion, with projected non-GAAP earnings per share in the range of $4.30 to $4.40 [3] Group 4: Acrivon Therapeutics, Inc. - Acrivon Therapeutics, Inc. (ACRV) rose 6.44% to $3.14 after announcing plans to release clinical data updates for ACR-368 and ACR-2316 on January 8, 2026 [4] Group 5: Other Companies - AnaptysBio, Inc. (ANAB) advanced 1.75% to $46.00 after confirming that CEO Daniel Faga will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 [5] - Omeros Corp. (OMER) added 4.47% to $14.72 without any new corporate updates [6] - EUDA Health Holdings Limited (EUDA) increased 3.73% to $2.50 after amending its warrant agreement with Streeterville Capital, LLC [6] - TherapeuticsMD, Inc. (TXMD) rose 5.34% to $2.15 in after-hours trading, with no new announcements reported [6] - Pyxis Oncology, Inc. (PYXS) gained 4.93% to $1.49 without any fresh news [7]

Core Viewpoint - Globus Medical's preliminary fourth quarter 2025 financial results and fiscal 2026 guidance have positively influenced investor sentiment, leading to a significant increase in share price after hours trading [1][3]. Financial Performance - Globus Medical projects a 25.2% year-over-year sales growth for Q4 2025, estimating revenue of $823.2 million, which exceeds analysts' expectations of $778.3 million [3]. - For fiscal 2026, the company has provided revenue guidance of $3.18 billion to $3.22 billion and diluted adjusted earnings per share (EPS) guidance of $4.30 to $4.40, surpassing the analyst consensus of $4.12 [4]. Market Valuation - Despite the recent increase in share price, Globus Medical's stock is currently valued at 30.2 times trailing earnings, which is a discount compared to its five-year average P/E of 44.5, suggesting potential investment opportunities for those interested in healthcare stocks focused on orthopedic and spinal care [5][6].